Atlas Trials

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Clinical trial NCT05000710 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05000710
Sponsor
Sheba Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic or Locally Advanced NSCLC
Start date
2021-12-09
Primary completion
2026-12-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.